Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology


Pfizer, Teva Settle Patent Litigation on Viagra

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

AstraZeneca Issues Statement on Competitor to Nexium

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

GlaxoSmithKline To Invest in UK-Based Manufacturing

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

Roche, Prothena Form mAb Pact

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Teva Releases Financial Guidance Dependent on Copaxone Generic Competition

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

Pharmaceutical Industry Growth Rebounds in Five-Year Outlook

Annual growth in spending for medicines is expected to rise from 2-3% in 2013 to 5-7% in 2017, the highest pace of growth since 2009.

AstraZeneca, Bristol-Myers Squibb Recall Certain Lots of Bydureon

AstraZeneca, Bristol-Myers Squibb recall certain lots of of their antidiabetes drug Bydureon (eventide) due to manufacturing records that batches may contain underfilled vials.

Elan Proceeds with Formal Sale Process of Company; Royalty Pharma Drops Bid

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.

Elan Board Rejects Multibillion Takeover Bid from Royalty Pharma

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.